Calcium acetate/magnesium carbonate - Fresenius Medical Care

Drug Profile

Calcium acetate/magnesium carbonate - Fresenius Medical Care

Alternative Names: OsvaRen; Rephoren

Latest Information Update: 27 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fresenius Medical Care
  • Class Acetates; Elements; Inorganic chemicals; Small molecules
  • Mechanism of Action Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 27 Sep 2017 Discontinued - Phase-II/III for Hyperphosphataemia in Germany (PO,granules)
  • 01 Jun 2015 Fresenius Medical Care completes a phase II/III trial in Hyperphosphataemia in Germany (NCT02027662)
  • 01 Jan 2014 Phase-II/III clinical trials in Hyperphosphataemia in Germany (PO, granules)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top